Skip to content

Released Aug 4, 2020, after the close

10-Q filed Aug 4, 2020, 35 days after period end · 0001232524-20-000054

Q2 2020 · 10-Q
Revenue$562.44M+5.3% vs Q2 2019+5.2% vs Q1 2020
Net Income$114.80M−56.2% vs Q2 2019N/M vs Q1 2020
EPS Diluted$2.06−54.8% vs Q2 2019N/M vs Q1 2020
Gross Profit$530,195,000+6.9%
Operating Income$198,126,000−3.0%
Operating Cash Flowderived$182,519,000+22.6%
Free Cash Flowderived$179,829,000+33.3%
Margins · derived
Gross margin94.3%+1.5 pt vs Q2 2019
Operating margin35.2%−3.0 pt vs Q2 2019
Net margin20.4%−28.6 pt vs Q2 2019

What the release said

The release

Same quarter

MetricQ2 2020Q2 2019Q2 2018Q2 2017
Revenue$562.44M$534.13M$500.48M$394.39M
Net Income$114.80M$261.90M$92.32M$105.60M
EPS Diluted$2.06$4.56$1.50$1.72

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR